Donepezil
donepezil hydrochloride — Aricept, Aricept ODT
Indications for Donepezil
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Mild to moderate Alzheimer disease dementia | Adults | Monotherapy or with memantine | FDA Approved |
| Moderate to severe Alzheimer disease dementia (includes severe) | Adults | Monotherapy or with memantine | FDA Approved |
Donepezil was first approved by the FDA in 1996 for mild to moderate Alzheimer disease, with approval for severe disease following in 2006. The 23 mg tablet was approved in 2010 for moderate to severe stages. Donepezil does not alter the underlying neurodegenerative pathology of Alzheimer disease but has demonstrated efficacy in slowing symptom progression by improving cognition and global function. It remains one of the most widely prescribed cholinesterase inhibitors worldwide and can be used alongside memantine (an NMDA antagonist) as combination therapy.
Dementia with Lewy bodies (DLB) — 5–10 mg daily. Approved in Japan for DLB; used off-label elsewhere. Phase 2 and 3 RCTs demonstrate improvements in cognition, hallucinations, and caregiver burden (Mori et al., 2012; Ikeda et al., 2015). Evidence quality: Moderate.
Parkinson disease dementia — 5–10 mg daily. Some evidence of cognitive and executive function improvement (Dubois et al., 2012), though trial results are mixed. Evidence quality: Low.
Vascular dementia — 5–10 mg daily. Two large RCTs showed modest cognitive improvement but FDA application was rejected; limited effect on global functioning. Evidence quality: Low.
Traumatic brain injury — 5–10 mg daily. Emerging evidence for memory dysfunction improvement. Evidence quality: Very Low.
Dosing
Donepezil Dosing by Clinical Scenario — Adults
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Mild to moderate Alzheimer disease — initial therapy | 5 mg once daily | 5–10 mg once daily | 10 mg/day | Do not increase to 10 mg until patient has been on 5 mg for 4–6 weeks Higher GI adverse events with 1-week titration vs 6-week titration |
| Moderate to severe Alzheimer disease — dose escalation | 5 mg once daily | 10–23 mg once daily | 23 mg/day | Must be on 10 mg/day for at least 3 months before escalating to 23 mg 23 mg tablet must be swallowed whole; do not split, crush, or chew |
| Severe Alzheimer disease | 5 mg once daily | 10–23 mg once daily | 23 mg/day | Same titration approach; higher rates of GI adverse effects and weight loss at 23 mg |
| Combination with memantine | 5 mg once daily | 10 mg once daily + memantine | 23 mg/day | Fixed-dose combination (Namzaric: memantine ER 28 mg / donepezil 10 mg) also available No pharmacokinetic interaction between the two agents |
| Lewy body dementia (off-label) | 3–5 mg once daily | 5–10 mg once daily | 10 mg/day | Approved in Japan for DLB; titrate slowly due to sensitivity in this population Monitor for worsening parkinsonism |
| Low body weight (<50 kg / <110 lb) | 5 mg once daily | 5 mg once daily | 10 mg/day | Higher plasma levels may increase adverse effects; titrate cautiously |
In the pivotal trials, patients titrated from 5 mg to 10 mg over one week experienced nausea (19%), diarrhea (15%), and insomnia (14%). When the same dose escalation was spread over six weeks, rates dropped to levels comparable to the 5 mg group (nausea 6%, diarrhea 9%, insomnia 6%). The FDA label now recommends waiting 4–6 weeks before escalating from 5 mg to 10 mg (FDA PI). Some clinicians prefer an even more gradual approach, starting at 2.5 mg (half tablet) for the first 1–2 weeks in frail elderly patients.
Pharmacology
Mechanism of Action
Donepezil is a reversible, non-competitive inhibitor of acetylcholinesterase (AChE), the enzyme responsible for hydrolysing acetylcholine (ACh) in the synaptic cleft. By blocking AChE, donepezil increases the concentration and duration of action of ACh at cholinergic synapses throughout the brain, partially compensating for the loss of cholinergic neurons that characterises Alzheimer disease. Donepezil is highly selective for AChE over butyrylcholinesterase, with approximately 1,250-fold greater affinity for the former. This selectivity may contribute to its relatively favourable peripheral side-effect profile compared with non-selective agents. Donepezil also readily crosses the blood-brain barrier, achieving brain concentrations approximately twice those observed in plasma.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | 100% relative oral bioavailability; Tmax 3–4 h (5/10 mg), ~8 h (23 mg); not affected by food or timing of administration; ODT bioequivalent to standard tablets | Once-daily dosing convenient; 23 mg tablet designed for slower absorption with higher Cmax (~2-fold vs 10 mg); take with or without food |
| Distribution | Vd 12–16 L/kg at steady state; 96% protein-bound (albumin ~75%, alpha-1-acid glycoprotein ~21%); crosses blood-brain barrier; brain:plasma ratio ~2:1 | Large Vd reflects extensive tissue distribution; high CNS penetration underlies therapeutic effect; steady state reached in ~15 days |
| Metabolism | Hepatic via CYP3A4 and CYP2D6; also glucuronidation; produces 4 major metabolites (2 active); CYP2D6 has minor role (~17% clearance reduction with CYP2D6 inhibitors) | CYP3A4 inhibitors (e.g., ketoconazole) increase donepezil exposure by ~36%; CYP3A4 inducers may reduce levels; low affinity for CYP enzymes means minimal impact on other drugs |
| Elimination | t½ ~70 h; CL/F 0.13–0.19 L/hr/kg; 57% renally excreted (17% unchanged), 15–20% in feces; linear PK over 1–10 mg range | Long half-life supports once-daily dosing and allows 4–7-fold accumulation at steady state; clearance unchanged in moderate renal impairment; decreased ~20% in alcoholic cirrhosis |
Side Effects
Adverse effect data below are drawn from pooled pivotal clinical trials of donepezil in mild to moderate Alzheimer disease (5 mg and 10 mg with 1-week titration vs placebo) and the 23 mg vs 10 mg controlled trial in moderate to severe disease. Most adverse effects are cholinomimetic in nature, dose-related, and often transient.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | 19% vs 6% placebo | Most common complaint; rate drops to 6% with 6-week titration; often resolves within 1–3 weeks without dose modification |
| Diarrhea | 15% vs 5% placebo | Cholinomimetic mechanism; encourage adequate hydration; usually transient |
| Insomnia | 14% vs 6% placebo | May be reduced by switching to morning dosing (not in FDA label, but widely used clinically) |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Vomiting | 8% (10 mg) vs 3% placebo; 9% (23 mg) vs 3% (10 mg) | Dose-related; may indicate need for slower titration; ensure adequate fluid intake |
| Muscle cramps | 8% (10 mg) vs 2% placebo | Cholinomimetic effect on neuromuscular junction; usually nocturnal |
| Fatigue / asthenia | 8% (10 mg) vs 3% placebo | May overlap with Alzheimer disease symptoms; assess for other causes |
| Anorexia / decreased appetite | 7% (10 mg) vs 2% placebo; 5% (23 mg) vs 2% (10 mg) | Monitor weight regularly; more pronounced at 23 mg |
| Weight loss | 5% (23 mg) vs 3% (10 mg) | 8.4% of patients on 23 mg lost ≥7% body weight vs 4.9% on 10 mg; clinically important in frail elderly |
| Dizziness | 5% (23 mg) vs 3% (10 mg) | Assess for orthostatic component and fall risk |
| Headache | 4% (23 mg) vs 3% (10 mg) | Usually transient; exclude other causes in elderly |
| Ecchymosis | 4–5% | Reported in pivotal trials; may reflect increased fall risk in elderly population |
| Urinary incontinence | 3% (23 mg) vs 1% (10 mg) | Cholinomimetic effect on bladder smooth muscle; may worsen pre-existing incontinence |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Bradycardia / heart block | Uncommon (~1–2%) | Days to weeks; any time | ECG if symptomatic; hold donepezil if HR <50 bpm or symptomatic bradycardia; avoid combining with other rate-slowing agents |
| Syncope | ~1–2% | Variable; may coincide with bradycardia | Cardiac evaluation; fall risk assessment; consider alternative cholinesterase inhibitor |
| GI bleeding / peptic ulcer | Rare | Any time; higher risk with NSAID co-use | Monitor for melena/haematemesis; co-prescribe PPI if NSAID required; discontinue if active bleeding |
| Seizures | Rare | Any time | May be indistinguishable from Alzheimer-related seizures; neurology review; consider discontinuation |
| QTc prolongation | Rare (post-marketing) | Variable | Avoid co-administration with other QT-prolonging drugs; ECG monitoring if risk factors present |
| Rhabdomyolysis | Very rare (post-marketing) | Variable | Check CK if myalgia with dark urine; discontinue donepezil and hydrate aggressively |
| Neuroleptic malignant syndrome | Very rare (post-marketing) | Variable | Immediate discontinuation; ICU care; supportive measures |
| Reason for Discontinuation (Severe AD) | Incidence | Context |
|---|---|---|
| Anorexia | 2% vs 1% placebo | Overlaps with weight loss concern |
| Nausea | 2% vs <1% placebo | Cholinomimetic; dose-related |
| Diarrhea | 2% vs 0% placebo | Usually resolves with continued treatment |
| Urinary tract infection | 2% vs 1% placebo | May reflect incontinence and related hygiene issues |
Nausea, vomiting, and diarrhea are the most frequent reasons patients stop donepezil. These effects are cholinomimetic, dose-dependent, and strongly influenced by titration speed. Strategies to improve tolerability include extending the titration from 5 mg to 10 mg over 6 weeks rather than 1 week, switching from bedtime to morning dosing if nightmares or insomnia occur, and ensuring the patient takes the medication with food despite it not being required pharmacokinetically. If GI symptoms are intolerable, switching to a transdermal formulation or an alternative cholinesterase inhibitor (rivastigmine patch, galantamine ER) may be considered.
Drug Interactions
Donepezil is metabolised by CYP3A4 and CYP2D6, but its affinity for these enzymes is low. In clinical studies, CYP3A4 inhibitors produced only modest increases in donepezil exposure (~36% with ketoconazole), and CYP2D6 inhibitors had even smaller effects (~17% clearance reduction). The more clinically important interactions are pharmacodynamic, involving cholinergic and cardiac pathways.
Monitoring
- Cognitive FunctionBaseline, 3–6 months, then annually
RoutineUse validated tools (MMSE, MoCA, ADAS-Cog) to assess treatment response. If no measurable benefit after 3–6 months of optimised dosing, reassess whether continuation is appropriate. Expect stabilisation rather than improvement in most patients. - Heart RateBaseline, after dose changes
RoutineDonepezil has vagotonic properties that can cause bradycardia or heart block, even in patients without known cardiac disease. Check pulse at each visit. ECG if symptomatic bradycardia, syncope, or concomitant use of beta-blockers or calcium channel blockers. - Body WeightEvery 3 months
RoutineWeight loss occurs in up to 8.4% of patients on 23 mg. Clinically significant in already frail elderly patients. Track weight trends and assess nutritional intake. Reduce dose if unexplained weight loss >5% occurs. - GI SymptomsFirst 4–6 weeks, then as needed
RoutineAssess nausea, vomiting, diarrhea, and appetite at each visit during titration. Most GI effects are transient and resolve within 1–3 weeks. If persistent, consider slower titration, morning dosing, or switch to alternative. - Behavioural SymptomsEach visit
RoutineAssess for agitation, aggression, hallucinations, and sleep disturbances. Donepezil can occasionally worsen behavioural symptoms in some patients. In DLB patients specifically, monitor for worsening parkinsonism. - GI BleedingIf NSAID co-use or GI history
Trigger-basedCholinesterase inhibitors increase gastric acid secretion. Monitor for occult or overt GI bleeding in patients with peptic ulcer history or concurrent NSAID/antiplatelet use. Consider PPI co-prescription. - Respiratory StatusIf asthma or COPD history
Trigger-basedCholinomimetic action may increase bronchial secretions and airway reactivity. Use with caution and monitor respiratory symptoms in patients with obstructive lung disease.
Contraindications & Cautions
Absolute Contraindications
- Known hypersensitivity to donepezil hydrochloride or piperidine derivatives (FDA PI).
- History of allergic contact dermatitis with donepezil transdermal system (Adlarity PI).
Relative Contraindications (Specialist Input Recommended)
- Sick sinus syndrome or other supraventricular conduction abnormalities — vagotonic effects may precipitate symptomatic bradycardia or heart block.
- Active peptic ulcer disease or upper GI bleeding — cholinesterase inhibitors increase gastric acid secretion.
- Pregnancy — animal data suggest potential fetal harm; no adequate human studies.
Use with Caution
- Asthma or COPD — cholinomimetic activity may exacerbate bronchoconstriction.
- Seizure history — cholinomimetics may lower the seizure threshold; however, seizure activity may also reflect Alzheimer disease itself.
- Bladder outflow obstruction — cholinomimetic effects may worsen urinary retention.
- Low body weight (<50 kg) — higher plasma concentrations may increase the risk of adverse effects; consider maintaining at 5 mg.
- Hepatic impairment — clearance reduced by approximately 20% in stable cirrhosis; formal dose adjustment not required but monitor more closely.
- Concurrent use of anticholinergic medications — negates the therapeutic benefit of donepezil.
Donepezil can cause clinically significant nausea and vomiting, particularly at the 23 mg dose level. These effects may be severe enough to result in dehydration in elderly patients. Weight loss of ≥7% of baseline body weight occurred in 8.4% of patients on 23 mg/day in the pivotal trial. The FDA PI advises that patients should be closely monitored for these effects, especially during dose escalation (FDA PI).
As a cholinesterase inhibitor, donepezil has vagotonic effects on the sinoatrial and atrioventricular nodes that may manifest as bradycardia or heart block in patients with and without known underlying cardiac conduction abnormalities. Syncopal episodes have been reported. Particular caution is warranted in patients with sick sinus syndrome or those receiving concurrent beta-blockers (FDA PI).
Patient Counselling
Purpose of Therapy
Donepezil is prescribed to help improve memory, thinking, and the ability to perform daily activities in people with Alzheimer disease. It works by boosting the levels of a natural chemical messenger (acetylcholine) in the brain that is reduced in Alzheimer disease. It is important for patients and caregivers to understand that donepezil does not cure or stop the progression of Alzheimer disease, but it may slow the worsening of symptoms for a period of time.
How to Take
Donepezil is taken once daily. The standard tablets (5 mg, 10 mg) can be taken with or without food, at any time of day, though bedtime dosing is the traditional recommendation. The 23 mg tablet must be swallowed whole and should never be split, crushed, or chewed. The orally disintegrating tablet (ODT) should be placed on the tongue, allowed to dissolve, and followed with water. If a dose is missed, take it as soon as remembered; if multiple days are missed (more than 7 days), contact the prescriber before restarting.
Sources
- ARICEPT (donepezil hydrochloride) tablets / ODT — Full Prescribing Information. Eisai Inc. / FDA. FDA Label (2018) Primary source for approved indications, dosing (5, 10, 23 mg), pharmacokinetics, adverse reactions tables, drug interactions, and contraindications.
- ARICEPT 23 mg — Full Prescribing Information. Eisai Inc. / FDA. FDA Label (2010) Source for 23 mg-specific adverse reactions, 23 mg vs 10 mg comparative trial data, and weight loss findings.
- Namzaric (memantine HCl extended-release / donepezil HCl) — Full Prescribing Information. Allergan / FDA. FDA Label (2017) Source for combination therapy pharmacokinetics; confirms no interaction between memantine and donepezil.
- Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia. 1996;7(6):293–303. doi:10.1159/000106895 Original pivotal 30-week RCT establishing donepezil 5 mg and 10 mg efficacy in mild to moderate Alzheimer disease.
- Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2018;(6):CD001190. doi:10.1002/14651858.CD001190.pub3 Comprehensive Cochrane review confirming modest but consistent cognitive and global function benefits across all AD severity stages.
- Mori E, Ikeda M, Kosaka K; Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Ann Neurol. 2012;72(1):41–52. doi:10.1002/ana.23557 Phase 2 RCT (n=140) in DLB demonstrating cognitive, behavioural, and global improvements at 5 and 10 mg.
- Ikeda M, Mori E, Matsuo K, et al. Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial. Alzheimers Res Ther. 2015;7(1):4. doi:10.1186/s13195-014-0083-0 Phase 3 confirmatory trial in DLB (n=142); basis for Japan DLB approval.
- Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413–446. doi:10.1016/S0140-6736(20)30367-6 Lancet Commission providing evidence-based framework for dementia treatment including cholinesterase inhibitor recommendations.
- Cummings J, Aisen P, Apostolova LG, et al. Aducanumab: appropriate use recommendations. J Prev Alzheimers Dis. 2021;8(4):398–410. doi:10.14283/jpad.2021.41 Provides contemporary context for cholinesterase inhibitor positioning alongside newer disease-modifying therapies.
- Prvulovic D, Schneider B. Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer’s disease. Expert Opin Drug Metab Toxicol. 2014;10(7):1039–1050. doi:10.1517/17425255.2014.915028 Detailed review of donepezil PK/PD including CYP enzyme interactions, AChE selectivity, and clinical exposure-response relationships.
- StatPearls: Donepezil. Chang C, et al. NCBI Bookshelf. Updated August 2023. NCBI Bookshelf Comprehensive clinical pharmacology overview covering mechanism, off-label uses, adverse effects, and monitoring.
- Tiseo PJ, Foley K, Friedhoff LT. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol. 1998;46(Suppl 1):56–60. doi:10.1046/j.1365-2125.1998.0460s1056.x Demonstrates unchanged donepezil clearance in moderate renal impairment, supporting no dose adjustment.
- Tiseo PJ, Perdomo CA, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol. 1998;46(Suppl 1):13–18. doi:10.1046/j.1365-2125.1998.0460s1013.x Key PK study characterising linear pharmacokinetics with evening dosing, protein binding (96%), half-life (~70 h), and AChE inhibition profile.
- Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer’s disease. Br J Clin Pharmacol. 2004;58(Suppl 1):1–8. doi:10.1111/j.1365-2125.2004.01848.x Comprehensive safety review covering GI, cardiovascular, and CNS tolerability across clinical trials.